Whipplewood Advisors LLC Trims Stake in argenex SE $ARGX

Whipplewood Advisors LLC reduced its position in shares of argenex SE (NASDAQ:ARGX) by 82.6% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47 shares of the company’s stock after selling 223 shares during the quarter. Whipplewood Advisors LLC’s holdings in argenex were worth $26,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its holdings in argenex by 14.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock worth $99,886,000 after purchasing an additional 21,805 shares during the period. Amundi increased its holdings in argenex by 8.1% during the 1st quarter. Amundi now owns 6,351 shares of the company’s stock worth $3,747,000 after purchasing an additional 478 shares during the period. Voya Investment Management LLC increased its holdings in argenex by 5.2% during the 1st quarter. Voya Investment Management LLC now owns 14,905 shares of the company’s stock worth $8,822,000 after purchasing an additional 735 shares during the period. Wealth Management Associates Inc. purchased a new position in shares of argenex in the 1st quarter valued at $268,000. Finally, Royal Bank of Canada increased its holdings in shares of argenex by 0.9% in the 1st quarter. Royal Bank of Canada now owns 38,306 shares of the company’s stock valued at $22,673,000 after acquiring an additional 353 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ARGX shares. Stifel Nicolaus set a $882.00 price target on argenex in a report on Thursday, September 18th. Royal Bank Of Canada initiated coverage on argenex in a report on Monday, August 25th. They issued an “outperform” rating and a $850.00 price target on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Wednesday, October 8th. Wall Street Zen raised argenex from a “hold” rating to a “buy” rating in a research report on Friday, October 3rd. Finally, Jefferies Financial Group set a $818.00 price objective on argenex and gave the stock a “buy” rating in a research report on Tuesday, August 26th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $817.53.

argenex Stock Performance

Shares of ARGX opened at $829.83 on Tuesday. The stock has a 50-day moving average of $756.03 and a two-hundred day moving average of $647.67. argenex SE has a one year low of $510.05 and a one year high of $855.46. The stock has a market cap of $51.09 billion, a P/E ratio of 42.56, a P/E/G ratio of 0.89 and a beta of 0.46.

argenex (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The business had revenue of $866.79 million during the quarter, compared to analyst estimates of $776.82 million. argenex had a return on equity of 21.06% and a net margin of 40.98%. Analysts predict that argenex SE will post 3.13 EPS for the current fiscal year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.